Edwards Lifesciences Corp.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It's Moving
Edwards Lifesciences Hits 52-Week High on Analyst Upgrades Fueling Momentum.
Shares of Edwards Lifesciences surged to a new 12-month peak above $87 amid fresh analyst upgrades, reflecting confidence in the medtech leader's growth trajectory. Investors are piling in as Wall Street raises targets, building on the company's recent earnings beat and robust outlook in heart device innovation.
- Royal Bank of Canada hiked its price target to $100 from $95 with an 'outperform' rating on December 5, propelling the stock to $87.61 intraday[1].
- Canaccord Genuity reiterated 'Hold' but lifted its target to $89 from $84 the same day, signaling 6% upside potential amid sector strength[2].
- Stock climbed steadily from $83.28 on Dec 9 to $84.24 by Dec 11, underscoring bullish technicals with analysts' 'Moderate Buy' consensus[7][4].
Edwards Lifesciences Hits 52-Week High on Analyst Upgrades Fueling Momentum.
Shares of Edwards Lifesciences surged to a new 12-month peak above $87 amid fresh analyst upgrades, reflecting confidence in the medtech leader's growth trajectory. Investors are piling in as Wall Street raises targets, building on the company's recent earnings beat and robust outlook in heart device innovation.
- Royal Bank of Canada hiked its price target to $100 from $95 with an 'outperform' rating on December 5, propelling the stock to $87.61 intraday[1].
- Canaccord Genuity reiterated 'Hold' but lifted its target to $89 from $84 the same day, signaling 6% upside potential amid sector strength[2].
- Stock climbed steadily from $83.28 on Dec 9 to $84.24 by Dec 11, underscoring bullish technicals with analysts' 'Moderate Buy' consensus[7][4].
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $93.74, indicating growth potential.
Financial Health
Edwards Lifesciences is showing strong revenue growth and profitability, supported by solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EW
Wearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
